The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1615
ISSUE 1615
January 11, 2021
Baloxavir (Xofluza) for Post-Exposure Prophylaxis of Influenza
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
January 11, 2021 (Issue: 1615)
The oral polymerase acidic endonuclease inhibitor
baloxavir marboxil (Xofluza — Genentech) is now FDAapproved
for post-exposure prophylaxis of influenza
in patients ≥12 years old. Baloxavir was approved for
treatment of acute uncomplicated influenza in patients
≥12 years old in 2018.1 Two neuraminidase inhibitors
are FDA-approved for prophylaxis of influenza:
oseltamivir (Tamiflu, and generics) in patients ≥1 year
old, and zanamivir (Relenza) in patients ≥5 years old.2
Unlike oseltamivir and zanamivir, baloxavir is not FDA-approved
for pre-exposure prophylaxis of influenza
during institutional or community outbreaks.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Baloxavir (Xofluza) for Post-Exposure Prophylaxis of Influenza
Article code: 1615b
Electronic, downloadable article - $45
Article code: 1615b
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
